Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00219609
Other study ID # A3871028
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received September 9, 2005
Last updated November 5, 2012
Start date January 2005
Est. completion date March 2006

Study information

Verified date November 2012
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To determine whether UK-390,957 is a safe treatment for premature ejaculation.


Recruitment information / eligibility

Status Completed
Enrollment 1058
Est. completion date March 2006
Est. primary completion date March 2006
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV

Exclusion Criteria:

- No drug related serious adverse events

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
UK-390,957


Locations

Country Name City State
Australia Pfizer Investigational Site Adelaide South Australia
Australia Pfizer Investigational Site Malvern Victoria
Australia Pfizer Investigational Site Nedlands Western Australia
Australia Pfizer Investigational Site Spring Hill Queensland
Australia Pfizer Investigational Site St Leonards New South Wales
Austria Pfizer Investigational Site Mistelbach
Austria Pfizer Investigational Site Salzburg
Canada Pfizer Investigational Site Barrie Ontario
Canada Pfizer Investigational Site London Ontario
Canada Pfizer Investigational Site Montréal Quebec
Canada Pfizer Investigational Site Montreal Quebec
Canada Pfizer Investigational Site Oakville Ontario
Canada Pfizer Investigational Site Toronto Ontario
Czech Republic Pfizer Investigational Site Brno
Czech Republic Pfizer Investigational Site Prague 5
Czech Republic Pfizer Investigational Site Praha 2
France Pfizer Investigational Site Lyon Cedex 03
Germany Pfizer Investigational Site Hamburg
Germany Pfizer Investigational Site Hannover
Germany Pfizer Investigational Site Muenchen
Israel Pfizer Investigational Site Beer Sheba
Israel Pfizer Investigational Site Haifa
Israel Pfizer Investigational Site Tel Hashomer
Israel Pfizer Investigational Site Tel-Aviv
Italy Pfizer Investigational Site Milan
Italy Pfizer Investigational Site Roma
Norway Pfizer Investigational Site Moelv
Norway Pfizer Investigational Site Oslo
Poland Pfizer Investigational Site Myslowice
Poland Pfizer Investigational Site Warszawa
Sweden Pfizer Investigational Site Skovde
Sweden Pfizer Investigational Site Stockholm
Turkey Pfizer Investigational Site Balcali Adana
Turkey Pfizer Investigational Site Balcova Izmir
Turkey Pfizer Investigational Site Samanpazari Ankara
United Kingdom Pfizer Investigational Site Devon
United Kingdom Pfizer Investigational Site Nr Lichfield Staffordshire
United States Pfizer Investigational Site Albany New York
United States Pfizer Investigational Site Anaheim California
United States Pfizer Investigational Site Atherton California
United States Pfizer Investigational Site Aurora Colorado
United States Pfizer Investigational Site Aventura Florida
United States Pfizer Investigational Site Beachwood Ohio
United States Pfizer Investigational Site Beverly Hills California
United States Pfizer Investigational Site Charlotte North Carolina
United States Pfizer Investigational Site Dallas Texas
United States Pfizer Investigational Site Durham North Carolina
United States Pfizer Investigational Site Edison New Jersey
United States Pfizer Investigational Site Endwell New York
United States Pfizer Investigational Site Evansville Indiana
United States Pfizer Investigational Site Fort Wayne Indiana
United States Pfizer Investigational Site Germantown Tennessee
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Indianapolis Indiana
United States Pfizer Investigational Site Kansas City Missouri
United States Pfizer Investigational Site Knoxville Tennessee
United States Pfizer Investigational Site Laguna Woods California
United States Pfizer Investigational Site Lexington Kentucky
United States Pfizer Investigational Site Madisonville Kentucky
United States Pfizer Investigational Site Memphis Tennessee
United States Pfizer Investigational Site Metairie Louisiana
United States Pfizer Investigational Site Milan Tennessee
United States Pfizer Investigational Site Milwaukee Wisconsin
United States Pfizer Investigational Site Milwuakee Wisconsin
United States Pfizer Investigational Site Minneapolis Minnesota
United States Pfizer Investigational Site New Brunswick New Jersey
United States Pfizer Investigational Site New Port Richey Florida
United States Pfizer Investigational Site New York New York
United States Pfizer Investigational Site Newport Beach California
United States Pfizer Investigational Site Portland Oregon
United States Pfizer Investigational Site Redwood City California
United States Pfizer Investigational Site Saint Clair Shores Michigan
United States Pfizer Investigational Site San Antonio Texas
United States Pfizer Investigational Site San Diego California
United States Pfizer Investigational Site Southhaven Mississippi
United States Pfizer Investigational Site Tarzana California
United States Pfizer Investigational Site Tucson Arizona
United States Pfizer Investigational Site Vorhees New Jersey
United States Pfizer Investigational Site Walnut Creek California
United States Pfizer Investigational Site Waterbury Connecticut
United States Pfizer Investigational Site Watertown Massachusetts
United States Pfizer Investigational Site West Seneca New York
United States Pfizer Investigational Site Williamsville New York

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia,  Austria,  Canada,  Czech Republic,  France,  Germany,  Israel,  Italy,  Norway,  Poland,  Sweden,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of safety
See also
  Status Clinical Trial Phase
Completed NCT01021670 - An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride Phase 4
Completed NCT00210613 - A Study of Withdrawal Effects With Dapoxetine in the Treatment of Premature Ejaculation Phase 3
Completed NCT00211107 - A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation. Phase 3
Completed NCT00219635 - Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation Phase 2/Phase 3
Terminated NCT02918227 - Exploration of Ejaculation Changing Mechanism After Surgery for Benign Prostatic Hyperplasia N/A
Completed NCT00219583 - Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation Phase 2/Phase 3
Completed NCT00143117 - Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation Phase 2/Phase 3
Completed NCT01366664 - A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin Phase 1
Completed NCT01230762 - An Open-Label Study of the Long-Term Safety of Dapoxetine HCl in the Treatment of Rapid Ejaculation Phase 3
Completed NCT00211094 - A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation Phase 3